Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute on Minority Health and Health Disparities (NIMHD)

Funding Opportunity Title
NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed)
Activity Code

U24 Resource-Related Research Projects – Cooperative Agreements

Announcement Type
New
Related Notices

None

Funding Opportunity Announcement (FOA) Number
RFA-MD-21-008
Companion Funding Opportunity
RFA-MD-21-007 , P50 Specialized Center
Number of Applications

Only one application per institution, as defined in Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)
93.307
Funding Opportunity Purpose

NIMHD invites applications from eligible institutions to establish a Research Coordinating Center (RCC) to support NIMHD P50 comprehensive research centers on prevention, treatment, and management of comorbid chronic diseases associated with health disparities authorized in Public Law 116-260, the Consolidated Appropriations Act of 2021. The RCC will coordinate activities across all of the chronic disease centers, including data collection; promoting collaboration and communication among investigators and the broader research community; promoting skills development of early stage investigators; coordinating and managing in-person and/or virtual meetings; and facilitating community engagement efforts.

Key Dates

Posted Date
April 14, 2021
Open Date (Earliest Submission Date)
May 11, 2021
Letter of Intent Due Date(s)

May 11, 2021

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
June 11, 2021 Not Applicable Not Applicable July 2021 August 2021 December 2021

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

No late applications will be accepted for this funding opportunity announcement.

Expiration Date
June 12, 2021
Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.


  4. Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

The purpose of this initiative is to establish a research coordinating center (RCC) to support 8-9 NIMHD P50 comprehensive research centers on the prevention, treatment, and management of comorbid chronic diseases associated with health disparities authorized by Public Law 116-260, the Consolidated Appropriations Act of 2021. The RCC will coordinate activities across all of these P50 multiple chronic disease (MCD) Centers, including data collection; promoting collaboration and communication among investigators and the broader research community; promoting skills development of early-stage investigators; coordinating and managing in-person and/or virtual meetings; and facilitating community engagement efforts.

Background

As the Nation’s steward of biomedical and behavioral research, NIH has devoted considerable resources to characterize the root causes of health disparities, uncovering complex webs of interconnected factors (e.g., behavioral, biological, social and environmental factors) acting at multiple levels across the life course. Despite this knowledge, insufficient progress has been made in reducing health disparities in morbidity and mortality related to chronic diseases. Tackling the complex drivers of health disparities requires a transdisciplinary framework that cuts across scientific and organizational silos to integrate multiple disciplines–behavioral, biological, and social sciences, epidemiology, data science, public health, health care delivery, economics, environmental science, public policy, and clinical research. It also requires strong collaborations between researchers, community organizations, health service providers, public health agencies, policymakers and other stakeholders to ensure that relevant, contextually appropriate research is conducted and, more importantly, that findings can be translated into sustainable community and system-level changes that promote health equity. In addition, research conducted at the regional level provides the opportunity to develop local coalitions of relevant stakeholders to address place-based determinants of health that may be specific to a region.

To pursue these objectives, NIMHD is supporting P50 research centers on health disparities in chronic diseases to leverage regional coalitions of research institutions and consortium partners focused on testing interventions implemented in real-world settings to reduce chronic disease disparities (see RFA-MD-21-007 for information on the scope of MCD Center activities). A Multiple Chronic Disease Research Coordinating Center (MCD-RCC) will be responsible for: 1) enabling collaboration and communication among investigators and the broader research community; 2) harmonizing research projects conducted across awardees including common data elements and data sharing; and 3) facilitating network outreach. Specific activities of the MCD-RCC will include, but are not limited to:

Scope of Activities for the Research Coordinating Center

Organization and Management

  • Coordination of administrative functions and data collection related to the MCD Centers research projects.
  • Promoting collaboration and communication among all MCD Centers investigators and the broader research community.
  • Planning, coordination, facilitation of in-person and virtual MCD Centers meetings including the startup meeting, monthly steering committee meetings, webinars, conference calls, an annual meeting, and other PD/PI meetings, as needed. These meetings are intended to identify areas of collaboration among awardees and will include a focus on determining how the expertise, facilities, and other resources of the awardees and their collaborators can contribute to ongoing and/or new projects, data sharing, and identifying opportunities for research involving awardees.
  • Report preparation including, but not limited to, an annual MCD Centers research report to be provided to NIMHD.
  • Coordination and management of outreach and communication about MCD Centers activities and dissemination of research findings; organizing sessions at scientific meetings; scheduling public lectures; and managing the social media presence
  • Development and maintenance of a secure, 508-compliant website. The website will serve dual functions as a public-facing resource as well as a portal reserved for awardees, NIH staff, and authorized users to promote sharing of information, expertise, technology development, and/or other areas of common interest.

Research Coordination and Data Analysis

  • Coordination of collaboration and resource sharing within the MCD Centers and dissemination of research resources (e.g., measurement instruments and procedures, protocols, statistical analysis tools, algorithms, study design resources, recruitment techniques, and study forms and templates).
  • In collaboration with the MCD Centers the development of common data elements, data and metadata standards, and data collection processes. Special attention to Tribal sovereignty in consent and data sharing with American Indian/Alaska Native communities is important.
  • Provide methodological consultation to MCD Center investigators on study design, regulatory compliance, biostatistics, bioinformatics and computational biology, data science, data management and analysis.
  • Assist in the development of IRB applications and/or coordinating IRB approvals, as needed.
  • Administration of a Data and Safety Monitoring Board (DSMB) to provide oversight, coordination, and support to MCD Centers awardees, as appropriate.
  • Ensure compliance with regulatory requirements and guidelines (i.e., clinical site and study monitoring for MCD Center awardees, conducting monitoring visits, developing and implementing QA/QC plans, providing regular GCP training to awardees, implementing skills development activities for all staff).
  • Assist individual MCD Center awardees and/or cross-awardee collaborations and activities such as support for pilot studies, multi-site projects, or other research projects. The responsibility for conduct and oversight of such projects will remain with the recipient awardee(s) consistent with NIH policies
  • Provide consultation on data harmonization for Social Determinants of Health (SDOH) using relevant measures via the PhenX Toolkit (www.phenxtoolkit.org). MCD Center investigators involved in human-subject studies were strongly encouraged to employ a common set of tools and resources that will promote the collection of comparable data on SDOH across studies.
  • Create a Data hub to warehouse deidentified data collected using a minimum set of common data elements from the NIMHD-funded MDC Centers. Develop agreements about the structure of content used across the MCD Centers to enable sharing aggregation and sharing. Integrated data across the MCD Centers consortium and administrative data should be available for secondary data analysis to MCD Center sites and the broader research and practice community.
  • Facilitate collaboration between MCD Centers and existing NIH or other federally funded cohorts, networks, and/or consortia to conduct chronic disease disparities research and disseminate findings, including but not limited to primary care practice-based research centers (PBRNs), or chronic disease or other research centers currently supported by NIMHD (see https://www.nimhd.nih.gov/programs/extramural/research-centers/), NCI (see https://www.cancer.gov/research/infrastructure/cancer-centers, NHLBI, NIDDK (see https://www.niddk.nih.gov/about-niddk/research-areas/research-centers), and/or NCATS (see https://ncats.nih.gov/ctsa).

Research Skills Development

  • Leverage resources across MCD Centers to assist with skills development to cultivate a cadre of investigators with the ability to bridge research and practice with a focus on eliminating disparities in chronic diseases and conditions.
  • Coordinate efforts to establish and maintain diverse skills development opportunities built upon the expertise of the MCD Centers that will address the needs of MCD researchers within various professions and settings (e.g., academic health centers, minority-serving institutions, community health workers, local and state departments of health, federally qualified health centers, senior centers, and other settings providing services for persons with MCD).
  • In collaboration with MCD Center awardees organize and conduct a yearly skills development workshop in conjunction with the annual MCD Centers awardees meetings.
  • Facilitate broad access to research mentors and other resources, including the NIH-funded National Research Mentoring Network that can enhance research skills development, particularly for MCD early-stageinvestigators from diverse backgrounds, including investigators from groups underrepresented in the biomedical research workforce (see Notice of NIH’s Interest in Diversity, https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html). and more-established MCD investigators seeking to expand their skill sets.
  • Track the extent to which investigator development activities at the MCD Centers, including but not limited to pilot project programs, will enhance the productivity of MCD Center investigators such as increased scientific publications, additional extramural research grant awards from NIH or other sources, etc.

Community Engagement

  • Monitor the extent to which community engagement activities at MCD Centers foster sustainable relationships with community-based organizations, enhance minority participation in research, and promote dissemination of research findings to communities to address their health-related concerns.
  • Establish a Community Advisory Board representing the broad spectrum of conditions and populations addressed by the MCD Centers.

Technical Assistance Webinar

NIMHD will conduct a technical assistance webinar for prospective applicants on May 4, 2021, at 3:00 PM Eastern Time. The Webinar connections will open 15 minutes in advance of the start time. NIMHD staff members involved in this FOA will provide orientation and technical assistance to potential applicants by explaining the goals and objectives of the MCD-RCC and answering questions from attendees. Prospective applicants are encouraged to send questions, preferably at least 24 hours prior to the webinar, to the Scientific/Research Contact(s).

To Join the Webinar, interested persons can use the WebEx meeting link or other connection information, as follows:

NIMHD Multiple Chronic Disease Centers Research Coordinating Center Technical Assistance Webinar

Tuesday, May 4, 2021

3:00 PM Eastern Time (US & Canada) 2 hrs

Meeting number (access code): 182 943 8108

Host key: 328674

Meeting password: MCDRCC

Join from the meeting link

https://nih.webex.com/nih/j.php?MTID=ma249f299ee5edb22717993c03c45a1f0

Join from a video system or application

Dial 1829438108@nih.webex.com">1829438108@nih.webex.com

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

+1-650-479-3208,,1829438108## Call-in toll number (US/Canada)

 

Join by phone

1-650-479-3208Call-in toll number (US/Canada)

Global call-in numbers

Join using Microsoft Lync or Microsoft Skype for Business

Dial 1829438108.nih@lync.webex.com">1829438108.nih@lync.webex.com

Need help? Go to http://collaborationhelp.cisco.com.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed
New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Not Allowed: Only accepting applications that do not propose clinical trials.

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIMHD intends to commit $4,500,000 in FY 2021 to fund one award.

Award Budget

Application budgets are limited to $3,000,000 in direct costs annually.

Award Project Period

The scope of the project should determine the project period. The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. 

Required Registrations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • eRA Commons - Applicants must have an active DUNS number to register in eRA Commons. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration, but all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

Yujing Liu, MD, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-7815
Email: liuyujin@mail.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

The MCD-RCC will be responsible for organizing and attending annual meetings meant to facilitate coordination among MCD Centers and any subcommittees in which they participate. The MCD-RCC application budget should include funds for organizing the annual meeting and for travel of the MCD-RCC PD(s)/PI(s) and other key personnel to the meeting. The MCD-RCC is not responsible for the travel of participants from individual MCD Centers.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy

Describe the organizational plan and management structure for providing leadership and administrative support for MCD-RCC activities and interactions with the MCD Centers and NIMHD. Applicants should consult RFA-MD-21-007 for information concerning the scope of the MCD Centers. Delineate the roles and responsibilities among key personnel at participating organizations. Include plans for ensuring accountability for achieving program objectives. Describe how the Steering Committee and any other advisory group(s) will be used to ensure successful completion of the stated aims. Applicants should avoid naming potential members of an advisory group, unless such persons have been consulted or contacted.

Describe how the MCD-RCC will work in close collaboration with the MCD Centers to facilitate and coordinate program activities nationally. Include plans for fostering communication and collaborative research arrangements between the MCD Centers, such as through arranging and hosting monthly PD/PI conference calls as well as similar calls and support for the various MCD Center Cores as needed, as well as providing logistical support to the MCD Centers and NIMHD staff to arrange a yearly MCD Center grantee meeting. Include plans and mechanisms for maintaining active involvement of all MCD Centers in all aspects of the program.

Describe plans and mechanisms for providing methodological consultation to MCD Center investigators on study design, regulatory compliance, biostatistics and other technical areas to augment expertise and research resources at individual MCD Centers.

Describe plans for developing and maintaining a secure Data hub to warehouse deidentified data, collect information on scientific advances from full research projects and pilot projects, as well as career development of pilot award recipients in MCD Centers. Include plans for working with MCD Centers to develop, adapt or use an existing set of minimum common structured data elements and performance metrics to assess progress on achieving programmatic objectives.

Describe how the MCD-RCC will support MCD Center activities aimed at diversifying the scientific workforce in basic biomedical research, behavioral and social sciences, and clinical research. Include plans and mechanisms to facilitate broad access to research mentors and other resources that can enhance the competitiveness and research skills development of investigators from diverse backgrounds, including investigators from groups underrepresented in the biomedical research workforce (see Notice of NIH’s Interest in Diversity, https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html) . Highlight how the relevant expertise of the MCD-RCC team will support these activities.

Describe plans to assist community engagement efforts at MCD Centers to: (1) develop/maintain strong working relationships with community partners, (2) increase minority participation in health-related research, and (3) promote timely dissemination of research findings to communities to help address their health-related concerns.

Describe how the MCD-RCC will function to serve as the MCD initiative’s point-of-contact for linking the MCD Centers with other NIMHD-funded Centers, other major NIH extramural programs, and the broader scientific community to promote collaborations in priority areas of basic biomedical research, behavioral and social sciences, and clinical research, especially in topics related to minority health and health disparities.

Describe plans and mechanisms for informing and making visible scientific advances of MCD Center investigators and affiliated scientists to the broader research community, policymakers, and other relevant stakeholders. Include plans for maintaining an up-to-date MCD-RCC website with links to each MCD Center and the NIMHD.

Applications must include a plan for evaluating all activities supported by the MCD-RCC, in line with the broader MCD Centers initiative program goals. The evaluation plan must specify baseline metrics to be included for the participating MCD Centers, e.g., numbers of research grant applications submitted and funded, research publications and other forms of scientific dissemination, scientific collaborations and partnerships, utilization/expansion of shared research resources and databases, as well as measures to gauge the short- and long-term success of the MCD-RCC in achieving its objectives.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

  • All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.
Appendix:
Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the proposed MCD-RCC address the needs of the MCD Centers that it will coordinate? Is the scope of activities proposed for the MCD-RCC appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the MCD centers?

To what extent are the proposed activities of the MCD-RCC likely to help MCD Centers achieve their primary goals and collectively advance the science of multiple chronic disease disparities nationally?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Are the PD(s)/PI(s) and other personnel well suited to their roles in the MCD-RCC? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing human subjects research? Do the investigators demonstrate significant experience with coordinating collaborative research? If the Center is multi-PD/PI, do the investigators have complementary and integrated expertise and skills; are their leadership, approach, governance, plans for conflict resolution, and organizational structure appropriate for the MCD-RCC? Does the applicant have experience overseeing selection and management of subawards, if needed?

Innovation

Does the application propose novel organizational concepts and management strategies in coordinating the projects the MCD-RCC will serve? Are the concepts and strategies novel to one type of research program or applicable in a broad sense? Is a refinement, improvement, or new application of organizational concepts and management strategies proposed?

Approach

Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the projects the MCD-RCC will serve? Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the projects, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the program is in the early stages of operation, does the proposed strategy adequately establish feasibility and manage the risks associated with the activities of the program? Are an appropriate plan for work-flow and a well-established timeline proposed? Have the investigators presented adequate plans to ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

To what extent are the proposed activities likely to foster programmatic coordination and scientific collaborations among MCD Centers and between MCD Centers and other research organizations? Are plans for periodic MCD Center grantee meetings (face-to-face and/or web-based) adequately described and justified, and are those meetings likely to foster productive relationships between participating institutions to help achieve MCD Center program goals?

To what extent are the proposed activities likely to enhance basic biomedical, behavioral and clinical research capacity across MCD Center institutions and help all levels of investigators at those institutions become more successful in obtaining competitive extramural support, particularly on chronic diseases that disproportionately impact populations that experience health disparities?

To what extent are the proposed activities likely to enhance the research skills and competitiveness of investigators from diverse backgrounds, including investigators from groups underrepresented in basic biomedical, behavioral and/or clinical sciences, particularly early-stage investigators?

Is there a well-formulated plan for supporting timely communication across MCD Centers as well as outreach to the broader research community and public, including an MCD-RCC website? Are proposed outreach plans likely to increase awareness of and interest in the MCD Centers program and participation in MCD-RCC-supported activities?

To what extent are the proposed activities likely to assist MCD Center institutions in establishing and/or enhancing sustainable working relationships with underserved communities and community-based organizations to foster and increase participation in research and the timely dissemination of research findings?

Environment

Will the institutional environment in which the MCD-RCC will operate contribute to the probability of success in facilitating the research program it serves? Are the institutional support, equipment and other physical resources available to the investigators adequate for the MCD-RCC proposed? Will the MCD-RCC benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?

Are plans to support technical consultation (e.g., study design, biostatistics, bioinformatics, data management and analyses, regulatory compliance) to investigators at MCD Centers adequately described and likely to be effective? Are there unique strengths or special expertise to enhance collaborative research efforts across MCD sites?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Individuals Across the Lifespan

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3)  Genomic Data Sharing Plan (GDS).

Data Sharing Plan: Are plans for developing and maintaining a Data hub to warehouse deidentified data collected using a minimum set of common data elements from the MDC Centers adequately described and likely to be effective? Are plans for maintaining a centralized database, through which MCD Center sites and NIMHD can track recruitment and retention of investigators from diverse backgrounds, including investigators from groups underrepresented in the biomedical research workforce and their productivity, along with outcomes of MCD Center-supported projects, adequately described and likely to be effective? Will data be collected in standardized, structured formats that are easily analyzable and shareable with authorized users? Are adequate safeguards in place to ensure data security?

Authentication of Key Biological and/or Chemical Resources:

For Centers involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMHD, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Minority Health and Health Disparities. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex. This includes ensuring programs are accessible to persons with limited English proficiency. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html.

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardee is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipient’s activities by involvement in and otherwise working jointly with the award recipient in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardee for the project as a whole, although specific tasks and activities may be shared among the awardee and the NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • Supporting the essential functions of the Multiple Chronic Disease Research Coordinating Center (MCD-RCC);
  • Working towards developing, adopting and implementing the agreed-upon policies, procedures, best practices, or other measures;
  • Providing information to the NIH Program Official and Project Scientist(s) concerning progress;
  • Participating in the overall coordination of NIMHD efforts in minority health and health disparities research; this participation may include collaboration and consultation with other research awardees, and the sharing of information, data and research materials.
  • Awardee will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

NIMHD will assign a Program Official and Project Scientist(s) to the MCD-RCC.

NIH Project Scientist(s) will have substantial scientific involvement during the conduct of this activity, through technical assistance, advice, and coordination. NIH Project Scientists(s) will:

  • Review and comment on critical stages in the program implementation;
  • Assist in coordinating activities with other ongoing studies supported through statewide, regional, or national programs to avoid duplication of efforts and encourage sharing and collaboration in the development of new research resources and methodologies;
  • Assist in the interaction between the awardee and investigators at other institutions to promote collaborations;
  • Assist in coordinating access to other research resources available through NIMHD and NIH-funded extramural programs;
  • Retain the option of recommending termination of support if technical performance or implementation falls below acceptable standards, or when specific key resources cannot be effectively implemented in a timely manner;
  • Retain the option to recommend additional infrastructure support within the constraints of the approved research and budget;
  • Convene meetings/workshops to address emerging areas of high priority.

Additionally, an NIMHD Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. The Program Official will:

  • Assist in enforcing general statutory, regulatory or administrative assistance policy requirements;
  • Evaluate progress by reviews of technical or fiscal reports or by site visits to determine that performance is consistent with objectives, terms and conditions of the award;
  • Ensure that activities proposed for development or implementation do not overlap or duplicate activities supported by other peer reviewed funding mechanisms;
  • Provide assistance in reviewing and commenting on all major changes of MCD-RCC activities prior to implementation to ensure consistency with the goals of this FOA;
  • Link the approaches developed by the MCD-RCC to other NIMHD-supported extramural programs to ensure that information is shared and utilized on the widest basis possible;
  • Monitor institutional commitments and resources to ensure that the MCD-RCC receives the maximum chance of stabilization and success;
  • Assist with financial oversight of the Program.

Additionally, the NIH Program Official may recommend the termination or curtailment of an activity in the event the proposed activities fail to evolve within the intent and purpose of this initiative.

Areas of Joint Responsibility include:

  • Establishing a Steering Committee consisting of: (a) the contact PD/PI of the MCD-RCC; (b) the contact PD/PI of the NIMHD-funded P50 Centers; (c) up to six other members selected by the MCD-RCC PD(s)/PI(s); and (d) the NIH Project Scientist(s). Each committee member will have one vote except for the NIH Project Scientists, who collectively will have one vote. In addition, the NIH Program Official and other NIH staff members may participate in Steering Committee meetings as non-voting members. The award recipient agrees to governance, through voting and decision-making consistent with applicable laws, regulations, and policies, of the MCD-RCC through this Steering Committee.
  • Identifying and facilitating partnerships between MCD Center awardees and other NIMHD award recipients in the respective regions with expertise and/or interest in health disparities or other relevant resources and expertise that could be leveraged to facilitate achievement of MCD Center program goals and objectives.
  • Organizing and participating in Steering Committee meetings to discuss matters of mutual interest and promote information exchange across MCD Center sites. Quarterly meetings of the Steering Committee will be held in the first year of the award, one of which must be an in-person meeting in Bethesda, MD. The frequency and venue(s) of meetings in succeeding years will be decided by the Steering Committee at the beginning of each budget period.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel will be convened, composed of three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Scientific/Research Contact(s)

Nathan Stinson, Jr, PhD, MD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8704
Email: stinsonn@mail.nih.gov

Peer Review Contact(s)

Yujing Liu, MD, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-7815
Email: liuyujin@mail.nih.gov

Financial/Grants Management Contact(s)

Priscilla Grant, JD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.